Stock 2QG QUANTUM GENOMICS
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Quantum Genomics Deutsche Boerse AG

Equities

2QG

FR0011648971

Market Closed - Deutsche Boerse AG
Other stock markets
 12:45:30 03/05/2024 pm IST 		5-day change 1st Jan Change
0.1164 EUR +1.22% Intraday chart for Quantum Genomics -0.51% +32.27%
13/03 Quantum Genomics Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Quantum Genomics Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Quantum Genomics : Quantum Genomics announces that it has obtained the approval of Shareholders on the reduction of its share capital and on the contribution in kind of 100% of ExactCure’s securities.
AT
Quantum Genomics : Quantum Genomics publishes its results for the 2023 financial year. The merger with ExactCure, which marks the strategic redeployment of the company and will be submiCed for a shareholder vote on April 24.
AT
Quantum Genomics : Quantum Genomics enters into exclusive negotiations with ExactCure
AT
Quantum Genomics : Quantum Genomics Releases First-Half 2023 Financial Results
AT
Quantum Genomics : Quantum Genomics announces resuming discussions with HealthTech companies following the termination of exclusive negotiations with Vistacare Medical
AT
Quantum Genomics : Quantum Genomics enters into exclusive negotiations with Vistacare Medical with the ambition of creating a reference player in the management of complex wounds
AT
Quantum Genomics : Quantum Genomics releases its 2022 financial results and provides an update on its MandA discussions
AT
Quantum Genomics : Quantum Genomics announces reorganization of its Board of Directors and staff restructuration in order to focus on new projects
AT
Quantum Genomics : Quantum Genomics gives an update
AT
Quantum Genomics : Quantum Genomics announces lack of significant efficacy for firibastat in their phase III study, FRESH and is redirecting to new developments
AT
Quantum Genomics Announces Lack of Significant Efficacy for Firibastat in Their Phase III Study, FRESH and is Redirecting to New Developments
AQ
Quantum Genomics : Quantum Genomics Announces the Next Meeting of its Scientific and Clinical Committee
AT
Quantum Genomics : 2022 Half-year financial report
PU
Quantum Genomics : Bryan Garnier and Co Initiates the Coverage of Quantum Genomics with a Target Price at 13 EUR per Share
AT
Bryan Garnier & Co Initiates the Coverage of Quantum Genomics with a Target Price at 13€ per Share
AQ
Quantum Genomics : Quantum Genomics Publishes its 2022 First Half Results and Reviews its Activity
AT
Quantum Genomics Publishes its 2022 First Half Results and Reviews its Activity
AQ
Quantum Genomics Announces That the Results Obtained with Firibastat in its Phase III Study, FRESH Will Now be Presented on November 7, 2022, During the AHA Conference in a Session Dedicated to Resistant Hypertension
AQ
Quantum Genomics : Quantum Genomics announces that it will present the results from its phase III FRESH study on difficult-to-treat and resistant hypertension at the annual American Heart Association (AHA) conference on November 4 , 2022
AT
Quantum Genomics announces the appointment of its new Scientific Advisory Board
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALQGC Stock
  4. 2QG Stock
  5. News Quantum Genomics
  6. Press Releases